Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
NCT02318329 · View on ClinicalTrials.gov ↗
Study Summary
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
Conditions Studied
Interventions
- DRUG FPA144
Study Locations (20)
Other
- Seoul National University Bundang Hospital — Seongnam-si
- Seoul National University Hospital — Seoul
- Severance Hospital, Yonsei University — Seoul
- Samsung Medical Center — Seoul
- Gangnam Severance Hospital — Seoul
- Korea University Anam Hospital — Seoul
California
- City of Hope Comprehensive Cancer Center — Duarte
- Ronald Reagan UCLA Medical Center — Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, Mission Bay — San Francisco
- Innovative Cancer Research Institute — Whittier
Tennessee
- Sarah Cannon Research Institute, LLC — Nashville
- Vanderbilt University Medical Center — Nashville
Texas
- The University of Texas M.D. Anderson Cancer Center — Houston
- South Texas Accelerated Research Therapeutics, LLC — San Antonio
Illinois
- The University of Chicago Medical Center — Chicago
Massachusetts
- Dana-Farber Cancer Institute — Boston
Michigan
- Karmanos Cancer Institute — Detroit
New York
- Weill Cornell Medical Center — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318329
The ClinicalTrials.gov registry entry for NCT02318329 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Prime Therapeutics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention — of which FPA144 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02318329 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02318329 about?
NCT02318329 is a clinical study titled "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors". This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
What is the current status of trial NCT02318329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2014-11. Estimated completion is 2019-06-30.
What conditions does trial NCT02318329 study?
This clinical trial studies the following conditions: Gastric Cancer, Advanced Solid Tumors, Transitional Cell Carcinoma of the Bladder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02318329?
The interventions under investigation include: FPA144 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02318329?
This trial is sponsored by Five Prime Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02318329 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.